Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VCEL with free AI briefings, catalyst countdowns, and dilution alerts.

VCEL · Vericel Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$235.6M Cash on Hand
CF+ Cash Runway
Follow VCEL by email Get an email when VCEL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VCEL, unsubscribe in one click. Privacy

📣 What VCEL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Carticel (autologous cultured chondrocyte)… Articular Cartilage Phase 4 · NCT00158613 Completed
autologous cultured chondrocytes on porcine… Chondral Defect Phase 3 · NCT06915233 Recruiting
Ixmyelocel-T Critical Limb Ischemia Phase 3 · NCT01483898 Completed
Autologous Cultured Chondrocytes Chondral Defect Phase 3 · NCT03588975 Recruiting
Bone Repair Cells (BRCs) Single Level Posterolateral Spinal Fusion Phase 1/2 · NCT00797550 Terminated
Cultured Bone Marrow Tissue Fracture, Ununited Phase 1/2 · NCT00424567 Terminated
Tissue Repair Cells (TRC) Alveolar Bone Loss Phase 1/2 · NCT00755911 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VCEL holds $235.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VCEL files for a raise →

👥 Who Owns VCEL

Insiders 1.2% Institutions (433 holders) 98.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 2,603,128 5.10% 2026-03-31
Dominick Colangelo
President and CEO, Director · +237,250 options
Insider 312,446 0.61% 2026-02-24
Jonathan Mark Hopper
Chief Medical Officer · +71,757 options
Insider 75,753 0.15% 2026-06-26
Alan L Rubino
Director · +11,200 options
Insider 64,194 0.13% 2026-04-29
Heidi Hagen
Director · +11,200 options
Insider 35,050 0.07% 2026-04-29
Robert L Md Zerbe
Director · +11,200 options
Insider 32,995 0.06% 2026-11-09
Paul K Wotton
Director · +11,200 options
Insider 18,802 0.04% 2026-05-11
Kevin F Mclaughlin
Director · +11,200 options
Insider 18,300 0.04% 2026-11-10
Michael Halpin
Chief Operating Officer · +89,250 options
Insider 16,394 0.03% 2026-08-03
Joseph Anthony Jr Mara
Chief Financial Officer · +251,011 options
Insider 16,186 0.03% 2026-11-09
Lisa Wright
Director · +11,200 options
Insider 15,851 0.03% 2026-04-29
Sean C. Flynn
Chief Legal Officer · +81,000 options
Insider 1,990 0.00% 2026-11-05

Share count 51,029,770 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VCEL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VCEL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.